Selank - Frequently Asked Questions

Selank is a synthetic tuftsin-analogue heptapeptide, described in the entry as a GABAergic and immunomodulatory neuropeptide. It is studied only in vitro and preclinically for neuro/immuno-signaling, with no therapeutic or human-use claim made.

Thr-Lys-Pro-Arg-Pro-Gly-Pro - a seven-residue peptide composed of the natural immunopeptide tuftsin (Thr-Lys-Pro-Arg) with an appended C-terminal Pro-Gly-Pro tail.

Its molecular weight is 751.87 g/mol (attributed to ChemicalBook), its molecular formula is C33H57N11O9, and its CAS number is 129954-34-3.

Selank adds a Pro-Gly-Pro tripeptide to the tuftsin core (Thr-Lys-Pro-Arg). That PGP tail resists cleavage by prolyl endopeptidases, which markedly extends stability over native tuftsin and improves blood-brain-barrier permeability in research models.

It is studied as a modulator of GABAergic neurotransmission and reported as a positive influence on GABA-receptor-associated signaling, alongside serotonergic effects and immunomodulatory activity on interferon and cytokine expression. In gene-expression studies it alters transcripts tied to GABAergic signaling and immunity.

Its immunomodulatory activity on interferon and cytokine expression reflects its tuftsin heritage: the Thr-Lys-Pro-Arg core is the natural immunopeptide tuftsin, so Selank is studied as a stabilized tuftsin analogue with retained immune-signaling character.

The single cited study, Volkova et al. (2016) in Frontiers in Pharmacology (DOI 10.3389/fphar.2016.00031; PMID 26941643), examines how Selank affects the expression of genes involved in GABAergic neurotransmission and immunity in the hippocampus.

Three: GABAergic neurotransmission gene-expression models; serotonergic and anxiolytic-pathway research; and tuftsin-derived immunomodulation (interferon/cytokine) studies.

Lyophilized Selank powder is dissolved in a measured volume of bacteriostatic water to form a defined-concentration stock, where concentration equals mass divided by volume. This is a laboratory in-vitro handling step only, not a human dosing protocol.

No numeric half-life or pharmacokinetic constant is provided. The only stability statement is qualitative: the PGP tail resists prolyl-endopeptidase cleavage and markedly extends stability over native tuftsin in research models. General peptide-class principles (cold, dry storage of lyophilized powder; reduced stability once in solution) are noted as general, not Selank-specific.

The engineered C-terminal Pro-Gly-Pro tail. Proline-rich termini are normally cleaved by prolyl endopeptidases, but the PGP arrangement resists that cleavage, which is credited with both extended stability over native tuftsin and improved blood-brain-barrier permeability in research models.

No. The entry states explicitly that all characterization is in-vitro and preclinical neuro/immuno-signaling, and that no therapeutic or human-use claim is made.